Epilepsy and epileptic syndrome.
Epilepsy and epileptic syndrome.
复制标题
DOI：
10.1007/978-1-4614-0653-2_8
复制
发表时间：
2012
影响因子：
--
通讯作者：
Galanopoulou AS
中科院分区：
文献类型：
--
作者：
Ono T;Galanopoulou AS
癫痫是最常见的神经系统疾病之一。在大多数癫痫患者中，癫痫发作对现有药物有反应。然而，相当数量的患者，特别是在医学上难治性癫痫的情况下，可能会出现不同程度的记忆或认知障碍、行为异常或精神症状，这可能会限制他们的日常功能。因此，在许多患者中，癫痫可能类似于神经退行性疾病。癫痫发作及其对大脑发育的潜在影响，癫痫发生的进行性可能在功能上改变涉及认知加工的大脑区域，与潜在病因有关的神经退行性过程，共病条件或表观遗传因素，如压力，药物，社会因素，都可能导致癫痫的进行性。临床和实验研究已经解决了癫痫发生和神经变性的发病机制。我们将主要关注局灶性癫痫最常见的病因之一颞叶癫痫的研究结果，这表明这两个过程都是进行性的，并利用共同或相互作用的途径。在本章中，我们将讨论其中的一些研究，神经保护治疗的潜在候选靶点，以及识别进展和癫痫发生的早期生物标志物的尝试，从而实施具有早发性疾病改善作用的治疗。
Epilepsy is one of the most common neurological disorders. In most patients with epilepsy, seizures respond to available medications. However, a significant number of patients, especially in the setting of medically-intractable epilepsies, may experience different degrees of memory or cognitive impairment, behavioral abnormalities or psychiatric symptoms, which may limit their daily functioning. As a result, in many patients, epilepsy may resemble a neurodegenerative disease. Epileptic seizures and their potential impact on brain development, the progressive nature of epileptogenesis that may functionally alter brain regions involved in cognitive processing, neurodegenerative processes that relate to the underlying etiology, comorbid conditions or epigenetic factors, such as stress, medications, social factors, may all contribute to the progressive nature of epilepsy. Clinical and experimental studies have addressed the pathogenetic mechanisms underlying epileptogenesis and neurodegeneration. We will primarily focus on the findings derived from studies on one of the most common causes of focal onset epilepsy, the temporal lobe epilepsy, which indicate that both processes are progressive and utilize common or interacting pathways. In this chapter we will discuss some of these studies, the potential candidate targets for neuroprotective therapies as well as the attempts to identify early biomarkers of progression and epileptogenesis, so as to implement therapies with early-onset disease-modifying effects.
登录
查看更多内容
影响因子：
5.7
作者：
Brooks-Kayal, Amy R.;Raol, Yogendra H.;Russek, Shelley J.
通讯作者：
Russek, Shelley J.
影响因子：
5.3
作者：
Cancedda, Laura;Fiumelli, Hubert;Poo, Mu-ming
通讯作者：
Poo, Mu-ming
影响因子：
2.5
作者：
Buckmaster, PS;Dudek, FE
通讯作者：
Dudek, FE
DOI：
10.1111/j.1749-6632.2003.tb07517.x
发表时间：
2003-01-01
期刊：
NEUROPROTECTIVE AGENTS
影响因子：
--
作者：
Bittigau, P;Sifringer, M;Ikonomidou, C
通讯作者：
Ikonomidou, C
影响因子：
11.2
作者：
CENDES, F;ANDERMANN, F;PETERS, T
通讯作者：
PETERS, T